Infliximab use in Crohn’s disease
- 22 April 2005
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 5 (4) , 589-599
Abstract
Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract. The disease can be quite severe, resulting in hospitalisation, requiring long-term treatment with a variety of medications and frequent surgeries. Infliximab is a chimeric monoclonal antibody directed against tumour necrosis factor, a key cytokine in the inflammatory cascade of many diseases, including Crohn’s disease. Numerous studies have shown significant improvement in both clinical and endoscopic luminal and fistulising Crohn’s disease with infliximab treatment. The clinical efficacy, indications, safety profile and future of infliximab are reviewed.Keywords
This publication has 47 references indexed in Scilit:
- Biologics in inflammatory bowel disease: how much progress have we made?Gut, 2004
- Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosaGut, 1999
- Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 1992
- Tumour necrosis factor alpha in stool as a marker of intestinal inflammationThe Lancet, 1992
- Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.Gut, 1991
- Tumor necrosis factor Characterization at the molecular, cellular and in vivo levelFEBS Letters, 1991
- Clinical, biological, and endoscopic picture of attacks of Crohn's diseaseGastroenterology, 1990
- Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation.Gut, 1990
- INHIBITORY EFFECT OF TNF$alpha; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITISThe Lancet, 1989
- The Biology of Cachectin/TNF -- A Primary Mediator of the Host ResponseAnnual Review of Immunology, 1989